Zuyderland Medisch Centrum Stichting — Clinical Trial Site

133 Registered trials

55 Currently recruiting

Organisation

Zuyderland Medisch Centrum Stichting

Location

Heerlen, Netherlands

Identifier

ORG-100023231

Address

Henri Dunantstraat 5, 6419 PC, Netherlands

Departments

#3356:Cardiology
#3719: Cardiology
#6001:Neurology
3024: Neurology
3719: Cardiology
5004:Pulmonology
7003: Rheumatology
Academisch MS Centrum Zuyderland
Atrium MC loc. Heerlen, dept. Internal medicine
Cardiology
Cardiology department
Dep of Cardiology
Department of Neurology
Department of Oncology
Department of orthopedic surgery
Department of pulmonology
Department of Respiratory Medicine
Department of Surgery
Dermatology
Endocrinologie
Gastroenterology
Gastroenterology, Geriatrics & Internal and Intensive Medicine
Gynaecology
Hematologie
Hematology
ICU
Internal Medicine
Internal Medicine - Hematology
Internal Medicine / Oncology
Internal Medicine and Oncology
Internal Medicine, Medical Oncology
Internal Medicine/oncology
interne geneeskunde
Longgeneeskunde
Longoncologie
Lung disease
MDL
Medical oncology
Medische Oncologie
N/A
Neurologie
Neurology
Neurosurgery
Not applicable
Obstetrics & Gynecology
Oncology
Orthopedic surgery
Pulmonary diseases
Pulmonary medicine
Pulmonary Science
Pulmonology
R&D Longziekte
R&D Longziekten
Reproductive medicine and gynecology
Rhematology
Rheumatology
Stichting Zuyderland Medisch Centrum
Surgery
urology
Zuyderland Medisch Centrum
Zuyderland Medisch Centrum( #1)
Zuyderland ziekenhuis
Zuyderland ziekenhuis_LOC#1

Clinical trials at this site (133)

Search interface

CLEAR-PATH trial Recruiting

2024-513363-15-01 (Chronic) Peripheral (occlusive) arterial disease (PAD) 11 2024-07-22
OSIBOOST 2: Improving Osimertinib cost-effectiveness in Non-Small Cell Lung Cancer treatment using dose-modification and pharmacokinetic boo… Recruiting

2023-505700-35-00 Non-Small Cell Lung Cancer with an EGFR driver mutation 4 2024-07-16
Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) Recruiting

2022-502968-20-02 Behcet's disease 4 2024-05-30
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting

2023-508586-33-00 multiple myeloma 5 2024-05-14
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting

2023-504899-25-00 Metastatic castration resistant prostate cancer 5 2024-04-04
VulVaccin study Recruiting

2023-506792-94-00 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSI 11 2024-03-04
The RiCOTTA study: Rifampicin Combination Therapy versus Targeted Antibiotic Monotherapy for Infected Joint Prostheses Caused by Staphylococ… Recruiting

2022-501620-26-00 prosthetic joint infection 6 2023-05-15
Peroperative Administration of Tranexamic acid in gastric bypass to reduce haemorrhage in patients with morbid obesity Recruiting

2024-513570-22-00 Morbid obesity 5 2023-04-28
WOEST-3 Recruiting

2022-502140-13-00 Atrial fibrillation Acute coronary syndrome Chronic cor 6 2023-01-11
Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting

2023-508389-13-00 Combined endpoint of all-cause mortality, kidney failur 5 2022-11-08
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination… Recruiting

2023-503442-30-00 Multiple Myeloma 5 2022-10-14
The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2… Recruiting

2024-513797-22-00 HER2 positive esophageal adenocarcinoma 5 2022-03-09
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
DRUP trial Recruiting

2023-509152-33-00 Advanced solid tumor 4 2016-07-25
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended

2024-512998-27-00 Non-Small Cell Lung Cancer 5 2025-02-21
Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed P… Ended

2024-518171-59-00 Prostate Cancer 11 2025-01-23
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended

2023-504359-29-01 Multiple sclerosis 5 2024-12-11
A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study Ended

2024-516511-24-00 Chronic myeloid leukaemia 11 2024-11-14
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
Safe Stop ipi-nivo Ended

2024-516938-34-00 Melanoma 5 2024-09-11
Combination therapy of 5-Fluorouracil and Calcipotriol versus 5-Fluorouracil in the treatment of Actinic Keratosis: a multicentre randomized… Ended

2024-511409-42-00 Actinic Keratosis 6 2024-09-02
DUTCH-WAIST Ended

2022-501392-81-00 Obesity 6 2024-07-25
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28